Zoetis Inc. Contract Liability (Deferred Revenue)
Zoetis Inc. (ZTS) had Contract Liability (Deferred Revenue) of $8.00 million as of 2021-06-30, per its 10-Q filed 2021-08-05.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2021-11-04
- 2021-06-30: Contract with Customer, Liability, Current $8.00M.
- 2021-03-31: Contract with Customer, Liability, Current $3.00M.
- 2020-12-31: Contract with Customer, Liability, Current $4.00M; Contract with Customer, Liability, Current as first filed $8.00M.
- 2020-09-30: Contract with Customer, Liability, Current $6.00M.
| Period end | Contract with Customer, Liability, Current | Contract with Customer, Liability, Current as first filed |
|---|---|---|
| 2021-06-30 | $8.00M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $3.00M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $4.00M 10-Q · filed 2021-11-04 | $8.00M 10-K · filed 2021-02-16 |
| 2020-09-30 | $6.00M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $5.00M 10-Q · filed 2021-08-05 | |
| 2020-03-31 | $3.00M 10-Q · filed 2021-05-06 | |
| 2019-12-31 | $11.00M 10-K · filed 2020-02-13 | |
| 2019-09-30 | $8.00M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $4.00M 10-Q · filed 2020-08-06 | |
| 2019-03-31 | $1.00M 10-Q · filed 2020-05-06 | |
| 2018-12-31 | $2.00M 10-K · filed 2019-02-14 | |
| 2018-09-30 | $2.00M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $2.00M 10-Q · filed 2019-08-06 | |
| 2018-03-31 | $2.00M 10-Q · filed 2019-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |